Sanofi secures exclusive rights to Ventyx Biosciences' CNS-penetrant candidate VTX3232 in a $27 million deal. This agreement grants Sanofi first negotiation rights for the potential neuroinflammatory treatment, boosting Ventyx's stock prices by 14.8%.